Skip to main content
Top
Published in: Inflammation Research 6/2012

Open Access 01-06-2012 | Original Research Paper

Serum IL-33 but not ST2 level is elevated in intermittent allergic rhinitis and is a marker of the disease severity

Authors: Joanna Glück, Barbara Rymarczyk, Barbara Rogala

Published in: Inflammation Research | Issue 6/2012

Login to get access

Abstract

Background

Th2 cells play an important role in intermittent allergic rhinitis (IAR). Interleukin (IL)-33 stimulates the production of Th2-associated cytokines. IL-33 binds to ST2 receptor which is highly expressed on mast cells and selectively on Th2 cells. IL-33 and ST2 might be involved in the Th2-mediated immune response.

Objective

We analyzed the serum level of IL-33 and its receptor ST2 in patients with IAR sensitive to grass and/or tree pollen to assess if the serum level of IL-33 and/or ST2 may be a marker of the disease severity.

Methods

IL-33, ST2 and total immunoglobulin (Ig) E were measured in sera of patients with IAR sensitive to birch and/or grass pollen and in patients with controlled bronchial asthma and in non-allergic controls. IAR severity was assessed by total nasal symptom score.

Results

Serum levels of IL-33 in patients with IAR were comparable with patients with bronchial asthma and were significantly higher in patients with IAR (P = 0.0035) and in patients with bronchial asthma (P = 0.008) than in controls. Serum levels of IL-33 correlated with disease severity.

Conclusion

Elevated level of IL-33 in sera of patients with IAR sensitive to tree and/or grass pollen and the correlation of IL-33 with the disease severity suggest that IL-33 is involved in the pathogenesis of intermittent allergic rhinitis.
Literature
1.
go back to reference Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol. 2007;37:2779–86.PubMedCrossRef Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol. 2007;37:2779–86.PubMedCrossRef
2.
go back to reference Cl Hsu, Neilsen CV, Bryce PJ. IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS One. 2010;3(5):e11944. Cl Hsu, Neilsen CV, Bryce PJ. IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS One. 2010;3(5):e11944.
3.
go back to reference Moulin D, et al. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine. 2007;40:216–25.PubMedCrossRef Moulin D, et al. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine. 2007;40:216–25.PubMedCrossRef
4.
go back to reference Ho LH, et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-Fc epsilon RI signals. J Leukoc Biol. 2007;82:1481–90.PubMedCrossRef Ho LH, et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-Fc epsilon RI signals. J Leukoc Biol. 2007;82:1481–90.PubMedCrossRef
5.
go back to reference Iikura M, et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest. 2007;87:971–8.PubMedCrossRef Iikura M, et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest. 2007;87:971–8.PubMedCrossRef
6.
go back to reference Lohning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA. 1998;95:6930–5.PubMedCrossRef Lohning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA. 1998;95:6930–5.PubMedCrossRef
7.
go back to reference Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med. 1998;187:787–94.PubMedCrossRef Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med. 1998;187:787–94.PubMedCrossRef
8.
go back to reference Lecart S, Lecointe N, Subramaniam A, et al. Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface. Eur J Immunol. 2002;32:2979–87.PubMedCrossRef Lecart S, Lecointe N, Subramaniam A, et al. Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface. Eur J Immunol. 2002;32:2979–87.PubMedCrossRef
9.
go back to reference Oshikawa K, Kuroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med. 2001;164:277–81.PubMed Oshikawa K, Kuroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med. 2001;164:277–81.PubMed
10.
go back to reference Ali M, Zhang G, Thomas WR, et al. Investigations into the role of ST2 in acute asthma in children. Tissue Antigens. 2009;73:206–12.PubMedCrossRef Ali M, Zhang G, Thomas WR, et al. Investigations into the role of ST2 in acute asthma in children. Tissue Antigens. 2009;73:206–12.PubMedCrossRef
11.
go back to reference Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem. 2007;282:26369–80.PubMedCrossRef Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem. 2007;282:26369–80.PubMedCrossRef
12.
go back to reference Shimizu M, Matsuda A, Yanagisawa K, et al. Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum Mol Genet. 2005;14:2919–27.PubMedCrossRef Shimizu M, Matsuda A, Yanagisawa K, et al. Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum Mol Genet. 2005;14:2919–27.PubMedCrossRef
13.
go back to reference Savenije OE, Kerkhof M, Reijmerink NE, et al. Interleukin-1 receptor-like 1 polymorphisms are associated with serum IL1RL1-a, eosinophils, and asthma in childhood. J Allergy Clin Immunol. 2011;127:750–6. e1–5.PubMedCrossRef Savenije OE, Kerkhof M, Reijmerink NE, et al. Interleukin-1 receptor-like 1 polymorphisms are associated with serum IL1RL1-a, eosinophils, and asthma in childhood. J Allergy Clin Immunol. 2011;127:750–6. e1–5.PubMedCrossRef
14.
go back to reference Pushparaj PN, Tay HK, H’ng SC, et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA. 2009;106:9773–8.PubMedCrossRef Pushparaj PN, Tay HK, H’ng SC, et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA. 2009;106:9773–8.PubMedCrossRef
15.
go back to reference Lloyd CM. IL-33 family members and asthma—bridging innate and adaptative immune response. Curr Opin Immunol. 2010;22:800–6.PubMedCrossRef Lloyd CM. IL-33 family members and asthma—bridging innate and adaptative immune response. Curr Opin Immunol. 2010;22:800–6.PubMedCrossRef
16.
go back to reference Prefontaine D, Nadigel J, Chouciali F, et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol. 2010;125:752–4.PubMedCrossRef Prefontaine D, Nadigel J, Chouciali F, et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol. 2010;125:752–4.PubMedCrossRef
17.
go back to reference Sakashita M, Yoshimoto T, Hirota T, et al. Association of serum interleukin-33 level and the interleukin-33 genetic variant with Japanese cedar pollinosis. Clin Exp Allergy. 2008;38:1875–81.PubMedCrossRef Sakashita M, Yoshimoto T, Hirota T, et al. Association of serum interleukin-33 level and the interleukin-33 genetic variant with Japanese cedar pollinosis. Clin Exp Allergy. 2008;38:1875–81.PubMedCrossRef
18.
go back to reference Bousquet J, Khaltaev N, Cruz A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008. Allergy. 2008;63:8–160.PubMedCrossRef Bousquet J, Khaltaev N, Cruz A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008. Allergy. 2008;63:8–160.PubMedCrossRef
20.
go back to reference Dreborg S, Frew A. Position papers: allergen standardization and skin tests. Allergy. 1993;48:9–82.CrossRef Dreborg S, Frew A. Position papers: allergen standardization and skin tests. Allergy. 1993;48:9–82.CrossRef
21.
go back to reference Miller A. Role of IL-33 in inflammation and disease. J Inflamm. 2011;8:22–33.CrossRef Miller A. Role of IL-33 in inflammation and disease. J Inflamm. 2011;8:22–33.CrossRef
22.
go back to reference Miller AM, Asquith DL, Hueber AJ, et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res. 2010;107:650–8.PubMedCrossRef Miller AM, Asquith DL, Hueber AJ, et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res. 2010;107:650–8.PubMedCrossRef
23.
go back to reference Matsuba-Kitamura S, Yoshimoto T, Yasudal K, et al. Contribution of IL-33 to induction and augmentation of experimental allergic conjunctivitis. Int Immunol. 2010;22:479–89.PubMedCrossRef Matsuba-Kitamura S, Yoshimoto T, Yasudal K, et al. Contribution of IL-33 to induction and augmentation of experimental allergic conjunctivitis. Int Immunol. 2010;22:479–89.PubMedCrossRef
25.
go back to reference Ober C, Yao TC. The genetics of asthma and allergic disease: a 21st century perspective. Immunol Rev. 2011;242:10–30.PubMedCrossRef Ober C, Yao TC. The genetics of asthma and allergic disease: a 21st century perspective. Immunol Rev. 2011;242:10–30.PubMedCrossRef
26.
go back to reference Kurokawa M, Matsukura S, Kawaguchi M, et al. Expression and effects of IL-33 and ST2 in allergic bronchial asthma: IL-33 induces eotaxin production in lung fibroblasts. Int Arch Allergy Immunol. 2011;155(Suppl 1):12–20.PubMedCrossRef Kurokawa M, Matsukura S, Kawaguchi M, et al. Expression and effects of IL-33 and ST2 in allergic bronchial asthma: IL-33 induces eotaxin production in lung fibroblasts. Int Arch Allergy Immunol. 2011;155(Suppl 1):12–20.PubMedCrossRef
Metadata
Title
Serum IL-33 but not ST2 level is elevated in intermittent allergic rhinitis and is a marker of the disease severity
Authors
Joanna Glück
Barbara Rymarczyk
Barbara Rogala
Publication date
01-06-2012
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 6/2012
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-012-0443-9

Other articles of this Issue 6/2012

Inflammation Research 6/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine